相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Microglial phenotypes in Parkinson's disease and animal models of the disease
Valerie Joers et al.
PROGRESS IN NEUROBIOLOGY (2017)
Nanoparticle transport across in vitro olfactory cell monolayers
Oihane Gartziandia et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Intranasal Administration of Chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease
O. Gartziandia et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2016)
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Wolfgang Oertel et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration
Oihane Gartziandia et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2015)
Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters
Brijesh Shah et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: A promising approach for the treatment of defective telomerase disorders
Susana P. Egusquiaguirre et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease
Eduardo Anitua et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Disease-Modifying Strategies for Parkinson's Disease
Lorraine V. Kalia et al.
MOVEMENT DISORDERS (2015)
Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting
Omidreza Jafarieh et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2015)
Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery
Sumit Sharma et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2014)
Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease
Chi Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
The blood-brain barrier: Structure, function and therapeutic approaches to cross it
Marta Tajes et al.
MOLECULAR MEMBRANE BIOLOGY (2014)
Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats
Ying-Zheng Zhao et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Parkinson's disease: animal models and dopaminergic cell vulnerability
Javier Blesa et al.
FRONTIERS IN NEUROANATOMY (2014)
The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview
Per G. Djupesland et al.
THERAPEUTIC DELIVERY (2014)
Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles
T. Kanazawa et al.
BIOMATERIALS (2013)
Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model
Shadab Md et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease
Enara Herran et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2013)
GDNF, NGF and BDNF as therapeutic options for neurodegeneration
Shelley J. Allen et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
Mohammad Fazil et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Animal models of Parkinson's disease
Fabio Blandini et al.
FEBS JOURNAL (2012)
Nanotechnology for neurodegenerative disorders
Francesca Re et al.
MATURITAS (2012)
Astrocyte-derived GDNF is a potent inhibitor of microglial activation
Sandra Moreira Rocha et al.
NEUROBIOLOGY OF DISEASE (2012)
Neurotrophic factors for the treatment of Parkinson's disease
Aideen M. Sullivan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2011)
Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals
Yao Qin et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Long-Term Neuroprotection and Neurorestoration by Glial Cell-Derived Neurotrophic Factor Microspheres for the Treatment of Parkinson's Disease
Elise Garbayo et al.
MOVEMENT DISORDERS (2011)
Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease
E. Garbayo et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium
Alpesh Mistry et al.
JOURNAL OF DRUG TARGETING (2009)
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Etienne C. Hirsch et al.
LANCET NEUROLOGY (2009)
Parkinson's disease and growth factors - are they the answer?
Roger A. Barker
PARKINSONISM & RELATED DISORDERS (2009)
The influence of microglia on the pathogenesis of Parkinson's disease
Caitriona M. Long-Smith et al.
PROGRESS IN NEUROBIOLOGY (2009)
Intranasal delivery: Physicochemical and therapeutic aspects
Henry R. Costantino et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007)
P53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain
Makio Mogi et al.
NEUROSCIENCE LETTERS (2007)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Regulation of microglial activities by glial cell line derived neurotrophic factor
YP Chang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease
C Jollivet et al.
BIOMATERIALS (2004)
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
A Schober
CELL AND TISSUE RESEARCH (2004)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Genomic medicine: Alzheimer's disease and Parkinson's disease
RL Nussbaum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration
PL McGeer et al.
ANNALS OF NEUROLOGY (2003)
分享论文
